GlassScriptPhysician profile
Ramneet Wadehra
NPI 1205031614
$6,760.44
in general payments reported to CMS, 2019-2025
28 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $553 · 2021: $519 · 2022: $1,284 · 2023: $1,046 · 2024: $1,061 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $907.40 | 2019-2025 | |
| Boston Scientific Corporation | $837.38 | 2019-2025 | Accolade Sr, Watchman Access System, Emblem Mri S-Icd |
| Abbott Laboratories | $826.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $594.73 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $475.92 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $339.60 | 2020-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.65 | 2019-2025 | Jardiance |
| Pfizer INC. | $313.71 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $275.54 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $246.67 | 2021-2024 | Verquvo |
| Atricure, INC. | $229.38 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $222.55 | 2021-2025 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $217.37 | 2023-2024 | Inpefa |
| Livanova USA, INC. | $181.81 | 2019 | |
| Amgen INC. | $164.92 | 2019-2025 | Repatha, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $132.06 | 2019-2022 | |
| Getinge USA Sales, LLC | $98.11 | 2019 | |
| Amarin Pharma, INC. | $71.32 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $48.27 | 2019-2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $47.27 | 2025 | |
| Novo Nordisk INC | $38.49 | 2019 | |
| Preventice Services, LLC | $37.03 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $36.63 | 2024 | Arcalyst |
| Cvrx, INC. | $30.91 | 2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $18.33 | 2023 | Assure Wcd |
| Scpharmaceuticals INC. | $17.04 | 2025 | |
| Glaxosmithkline, LLC. | $16.08 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramneet Wadehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.